::ODMA\MHODMA\iManage;200863;

RWW/TAD/ead(amg) 02/14/01

JUN 0 5 2001

TES PATENT AND TRADEMA

Applicants:

Gavin C. Hirst, Paul Rafferty, Kurt Ritter, David Calderwood, Helen

Twigger, Stephen St. Gallay

Application No.:

09/663,320

Group:

1614

Filed:

September 15, 2000

Examiner: Not Assigned

For:

KINASE INHIBITORS AS THERAPEUTIC AGENTS

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Assistant Commissioner for Patents.

Washington, D.C. 20231

2/14/01 Date

Signature

Typed or printed name of person signing certificate

REQUEST FOR CORRECTED FILING RECEIPT **FOR UTILITY APPLICATION**

Office of Initial Patent Examination

Customer Service Center

Assistant Commissioner for Patents

Washington, D.C. 20231

Sir:

We hereby request that the following items of information be corrected in the Filing Receipt for the subject application received in this office on February 13, 2001.

The errors and corrections appear below.

The correct address of David Calderwood is Framingham, Massachusetts

Enclosed are a copy of the Filing Receipt with changes noted in red, and a copy of the recently filed Declaration/Power of Attorney.

Pursuant to instructions in the February 29, 2000 O.G., we hereby request that the errors which are identified above be corrected in the captioned application to which this request for correction is directed. It is understood that the Patent Office will issue an automaticallygenerated, corrected Filing Receipt in this and, if applicable, any other affected applications.

Respectfully submitted,

HAMILTON, BROOK, SMITH & REYNOLDS, P.C.

Dishard W. Wagner

Richard W. Wagner

Registration No.: 34,480 Telephone: (781) 861-6240

Facsimile: (781) 861-9540





UNITED STATES FATENDALLY ENDINGEN FOR PATENTS

UNITED STATES FATENDALLY ENDINGTON, D.C. 20231

WWW.uspto.gov

APPLICATION NUMBER | FILING DATE | GRP ART UNIT | FIL FEE REC'D | ATTY.DOCKET.NO | DRAWINGS | TOT CLAIMS | IND CLAIMS

09/663,320

09/15/2000

1614

2622

2079.1042-001

88

1

21005 HAMILTON BROOK SMITH AND REYNOLDS, P.C. TWO MILITIA DR LEXINGTON, MA 02421-4799



Date Mailed: 02/08/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the PTO processes the reply to the Notice, the PTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Gavin C. Hirst, Marlborough, MA;
Paul Rafferty, Westborough, MA;
Kurt Ritter, Newton, MA;
David Calderwood, Newton, MA;
Helen Twigger, Nottingham, UNITED KINGDOM;
Stephen St. Gallay, Loughborough, UNITED KINGDOM;

Continuing Data as Claimed by Applicant

THIS APPLN CLAIMS BENEFIT OF 60/154,618 09/17/1999

Foreign Applications


If Required, Foreign Filing License Granted 12/06/2000

Title

Kinase inhibitors as therapeutic agents

Preliminary Class

514



Data entry by : DIXON, DOROTHY

Team : OIPE

Date: 02/08/2001

RECEIVED

JUN 0 5 2001

LICEMSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184

Title 35, United States Code, Section 184 TECH CENTER 1600/2900 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFF 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 36 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15 (b).

PLEASE NOTE the following information about the Filing Receipt:

- The articles such as "a," "an" and "the" are not included as the first words in the title of an application. They are considered to be unnecessary to the understanding of the title.
- The words "new," "improved," "improvements in" or "relating to" are not included as first words in the title of an application because a patent application, by nature, is a new idea or improvement.
- The title may be truncated if it consists of more than 600 characters (letters and spaces combined).
- The docket number allows a maximum of 25 characters.
- If your application was submitted under 37 CFR 1.10, your filing date should be the "date in" found on the Express Mail label. If there is a discrepancy, you should submit a request for a corrected Filing Receipt along with a copy of the Express Mail label showing the "date in."
- The title is recorded in sentence case.

Any corrections that may need to be done to your Filing Receipt should be directed to: